Global Antivenom Immunoglobulin 麻豆原创 Research Report 2024

Publication ID:

PB504248932

Publication Date:

April 19, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Antivenom Immunoglobulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Antivenom Immunoglobulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antivenom Immunoglobulin.
Report Scope
The Antivenom Immunoglobulin market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antivenom Immunoglobulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antivenom Immunoglobulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Segment by Type
Polyvalent Antivenom
Monovalent Antivenom
Segment by Application
Non-profit Institutions
Hospitals and Clinics
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antivenom Immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antivenom Immunoglobulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Antivenom Immunoglobulin 麻豆原创 Overview
1.1 Product Overview and Scope of Antivenom Immunoglobulin
1.2 Antivenom Immunoglobulin Segment by Type
1.2.1 Global Antivenom Immunoglobulin 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Polyvalent Antivenom
1.2.3 Monovalent Antivenom
1.3 Antivenom Immunoglobulin Segment by Application
1.3.1 Global Antivenom Immunoglobulin 麻豆原创 Value by Application: (2024-2030)
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinics
1.4 Global Antivenom Immunoglobulin 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Antivenom Immunoglobulin Revenue 2019-2030
1.4.2 Global Antivenom Immunoglobulin Sales 2019-2030
1.4.3 Global Antivenom Immunoglobulin 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antivenom Immunoglobulin 麻豆原创 Competition by Manufacturers
2.1 Global Antivenom Immunoglobulin Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Antivenom Immunoglobulin Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Antivenom Immunoglobulin Average Price by Manufacturers (2019-2024)
2.4 Global Antivenom Immunoglobulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antivenom Immunoglobulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antivenom Immunoglobulin, Product Type & Application
2.7 Antivenom Immunoglobulin 麻豆原创 Competitive Situation and Trends
2.7.1 Antivenom Immunoglobulin 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antivenom Immunoglobulin Players 麻豆原创 Share by Revenue
2.7.3 Global Antivenom Immunoglobulin 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antivenom Immunoglobulin Retrospective 麻豆原创 Scenario by Region
3.1 Global Antivenom Immunoglobulin 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antivenom Immunoglobulin Global Antivenom Immunoglobulin Sales by Region: 2019-2030
3.2.1 Global Antivenom Immunoglobulin Sales by Region: 2019-2024
3.2.2 Global Antivenom Immunoglobulin Sales by Region: 2025-2030
3.3 Global Antivenom Immunoglobulin Global Antivenom Immunoglobulin Revenue by Region: 2019-2030
3.3.1 Global Antivenom Immunoglobulin Revenue by Region: 2019-2024
3.3.2 Global Antivenom Immunoglobulin Revenue by Region: 2025-2030
3.4 North America Antivenom Immunoglobulin 麻豆原创 Facts & Figures by Country
3.4.1 North America Antivenom Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antivenom Immunoglobulin Sales by Country (2019-2030)
3.4.3 North America Antivenom Immunoglobulin Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antivenom Immunoglobulin 麻豆原创 Facts & Figures by Country
3.5.1 Europe Antivenom Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antivenom Immunoglobulin Sales by Country (2019-2030)
3.5.3 Europe Antivenom Immunoglobulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antivenom Immunoglobulin 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Antivenom Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antivenom Immunoglobulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Antivenom Immunoglobulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antivenom Immunoglobulin 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Antivenom Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antivenom Immunoglobulin Sales by Country (2019-2030)
3.7.3 Latin America Antivenom Immunoglobulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antivenom Immunoglobulin 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Antivenom Immunoglobulin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antivenom Immunoglobulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antivenom Immunoglobulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antivenom Immunoglobulin Sales by Type (2019-2030)
4.1.1 Global Antivenom Immunoglobulin Sales by Type (2019-2024)
4.1.2 Global Antivenom Immunoglobulin Sales by Type (2025-2030)
4.1.3 Global Antivenom Immunoglobulin Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Antivenom Immunoglobulin Revenue by Type (2019-2030)
4.2.1 Global Antivenom Immunoglobulin Revenue by Type (2019-2024)
4.2.2 Global Antivenom Immunoglobulin Revenue by Type (2025-2030)
4.2.3 Global Antivenom Immunoglobulin Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Antivenom Immunoglobulin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antivenom Immunoglobulin Sales by Application (2019-2030)
5.1.1 Global Antivenom Immunoglobulin Sales by Application (2019-2024)
5.1.2 Global Antivenom Immunoglobulin Sales by Application (2025-2030)
5.1.3 Global Antivenom Immunoglobulin Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Antivenom Immunoglobulin Revenue by Application (2019-2030)
5.2.1 Global Antivenom Immunoglobulin Revenue by Application (2019-2024)
5.2.2 Global Antivenom Immunoglobulin Revenue by Application (2025-2030)
5.2.3 Global Antivenom Immunoglobulin Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Antivenom Immunoglobulin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Antivenom Immunoglobulin Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Antivenom Immunoglobulin Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 BTG
6.3.1 BTG Corporation Information
6.3.2 BTG Description and Business Overview
6.3.3 BTG Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BTG Antivenom Immunoglobulin Product Portfolio
6.3.5 BTG Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Antivenom Immunoglobulin Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Haffkine Bio-Pharmaceutical
6.5.1 Haffkine Bio-Pharmaceutical Corporation Information
6.5.2 Haffkine Bio-Pharmaceutical Description and Business Overview
6.5.3 Haffkine Bio-Pharmaceutical Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Haffkine Bio-Pharmaceutical Antivenom Immunoglobulin Product Portfolio
6.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates
6.6 Rare Disease Therapeutics
6.6.1 Rare Disease Therapeutics Corporation Information
6.6.2 Rare Disease Therapeutics Description and Business Overview
6.6.3 Rare Disease Therapeutics Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Rare Disease Therapeutics Antivenom Immunoglobulin Product Portfolio
6.6.5 Rare Disease Therapeutics Recent Developments/Updates
6.7 Flynn Pharma
6.6.1 Flynn Pharma Corporation Information
6.6.2 Flynn Pharma Description and Business Overview
6.6.3 Flynn Pharma Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Flynn Pharma Antivenom Immunoglobulin Product Portfolio
6.7.5 Flynn Pharma Recent Developments/Updates
6.8 Vins Bioproducts
6.8.1 Vins Bioproducts Corporation Information
6.8.2 Vins Bioproducts Description and Business Overview
6.8.3 Vins Bioproducts Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Vins Bioproducts Antivenom Immunoglobulin Product Portfolio
6.8.5 Vins Bioproducts Recent Developments/Updates
6.9 Bharat Serums and Vaccines
6.9.1 Bharat Serums and Vaccines Corporation Information
6.9.2 Bharat Serums and Vaccines Description and Business Overview
6.9.3 Bharat Serums and Vaccines Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bharat Serums and Vaccines Antivenom Immunoglobulin Product Portfolio
6.9.5 Bharat Serums and Vaccines Recent Developments/Updates
6.10 Serum Biotech
6.10.1 Serum Biotech Corporation Information
6.10.2 Serum Biotech Description and Business Overview
6.10.3 Serum Biotech Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Serum Biotech Antivenom Immunoglobulin Product Portfolio
6.10.5 Serum Biotech Recent Developments/Updates
6.11 MicroPharm
6.11.1 MicroPharm Corporation Information
6.11.2 MicroPharm Antivenom Immunoglobulin Description and Business Overview
6.11.3 MicroPharm Antivenom Immunoglobulin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 MicroPharm Antivenom Immunoglobulin Product Portfolio
6.11.5 MicroPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antivenom Immunoglobulin Industry Chain Analysis
7.2 Antivenom Immunoglobulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antivenom Immunoglobulin Production Mode & Process
7.4 Antivenom Immunoglobulin Sales and 麻豆原创ing
7.4.1 Antivenom Immunoglobulin Sales Channels
7.4.2 Antivenom Immunoglobulin Distributors
7.5 Antivenom Immunoglobulin Customers
8 Antivenom Immunoglobulin 麻豆原创 Dynamics
8.1 Antivenom Immunoglobulin Industry Trends
8.2 Antivenom Immunoglobulin 麻豆原创 Drivers
8.3 Antivenom Immunoglobulin 麻豆原创 Challenges
8.4 Antivenom Immunoglobulin 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.